Avandia Restricted in US, Banned in Europe

Avandia, GlaxoSmithKline’s controversial diabetes drug, will have its sales restricted in the US and altogether removed from the European marketplace. The moves come after a long series of reports and studies that Avandia increases the risk of heart attacks and strokes in diabetes patients. Some reports have also expressed concerns about Avandia’s effectiveness especially in comparison with other diabetes drugs such as rival Actos.
According to the Wall St. Journal, “The FDA will require GlaxoSmithKline to develop a restricted access program for Avandia that would make it available only if other types of drugs fail to properly treat diabetes. Patients currently taking Avandia can continue on the medication.”